USPTO Art Unit 1627 Prosecution Statistics

Art Unit Information

Art Unit: 1627
Group: 1620
Tech Center: 1600
Total Cases: 15,223
Last Active: January 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19038538WRN INHIBITORSJanuary 2025April 2025Allow210NoNo
19038543WRN INHIBITORSJanuary 2025April 2025Allow200YesNo
19030481MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTSJanuary 2025June 2025Abandon510NoNo
18999331ACYLSULFONAMIDE KAT6A INHIBITORSDecember 2024April 2025Allow410YesNo
18955261PHENETHYLAMINES AND CATHINONES PRECURSORSNovember 2024February 2025Allow300NoNo
18952842THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CHECKPOINT INHIBITOR-RESISTANT TUMORS USING PLINABULIN-BASED COMBINATION THERAPIESNovember 2024June 2025Allow611YesNo
18947694Liquid Tasimelteon Formulations and Methods of Use ThereofNovember 2024May 2025Allow610NoNo
18932827PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAMEOctober 2024May 2025Allow620YesNo
18932033HYDROCORTISONE ORAL LIQUID FORMULATIONSOctober 2024June 2025Allow720YesNo
18926907METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMENOctober 2024February 2025Allow310YesNo
18920212SMALL MOLECULE INHIBITORS OF KRAS PROTEINSOctober 2024March 2025Allow501NoNo
18916471METHODS AND COMPOSITIONS FOR TREATING EDEMA REFRACTORY TO ORAL DIURETICSOctober 2024April 2025Allow610YesNo
18901359PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIBSeptember 2024March 2025Allow510YesNo
18901530MODIFIED AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND SELECTED PSYCHIATRIC DISORDERSSeptember 2024May 2025Allow710YesNo
18897889ISOXAZOLINE PARASITICIDE FORMULATIONSSeptember 2024March 2025Allow610NoNo
188189262-(5-AMINOPYRIDIN-2-YL)-N-BENZYLACETAMIDES AND USE THEREOF IN THE TREATMENT OF ACUTE MYELOID LEUKEMIAAugust 2024March 2025Allow610NoNo
18794551PI3K INHIBITORSAugust 2024December 2024Allow501YesNo
18770514READY-TO-USE KETAMINE PREMIX FORMULATIONJuly 2024March 2025Allow821YesNo
18752072N-HETEROCYCLE SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USINGJune 2024December 2024Allow511NoNo
18721770DRUG COMBINATION FOR TREATMENT OF GASTRIC CANCERJune 2024April 2025Allow1020NoNo
18743946(E)-1-(2-(4-SUBSTITUTEDPHENYL)-2-OXOETHYL)-4-((HYDROXYIMINO)METHYL)PYRIDINIUM BROMIDES AS ANTITUBERCULAR AGENTSJune 2024September 2024Allow300NoNo
18742438PHENOXY AND BENZYLOXY SUBSTITUTED PSYCHOPLASTOGENS AND USES THEREOFJune 2024September 2024Allow300NoNo
18740610METHODS RELATED TO OPIOID THERAPEUTICSJune 2024January 2025Allow700NoNo
18732301INHIBITORS OF TYK2June 2024March 2025Allow920YesNo
18675317LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONSMay 2024April 2025Allow1021YesNo
18676249NICORANDIL DERIVATIVESMay 2024June 2025Allow1310YesNo
18670604METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENTMay 2024April 2025Abandon1110NoNo
18670580METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENTMay 2024March 2025Abandon910NoNo
18670588METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENTMay 2024March 2025Abandon910NoNo
18670556METHOD OF TREATMENT AND SELECTION OF PATIENTS BENEFITING FROM AGOMELATINE BASED ON EEG MEASUREMENTSMay 2024May 2025Abandon1110NoNo
18670524METHOD OF TREATMENT AND SELECTION OF PATIENTS BENEFITING FROM AGOMELATINE BASED ON EEG MEASUREMENTSMay 2024May 2025Abandon1110NoNo
18668653STABLE PHARMACEUTICAL COMPOSITION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG DERIVATIVEMay 2024June 2025Allow1310YesNo
18665714LIQUID ORAL FORMULATIONS FOR TADALAFILMay 2024November 2024Allow610NoNo
18660698ANTICANCER COMPOSITIONSMay 2024April 2025Allow1120NoNo
186584601-(4-CARBONOIMIDOYLPHENOXY)-3-{4-[(E)-(PHENYLIMINO)METHYL]PHENOXY}PROPAN-2-OL AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)May 2024August 2024Allow400YesNo
18651454COMPOSITIONS CONTAINING SHORT-CHAIN FATTY ACID, METHODS OF USE, AND METHODS OF MAKING THEREOFApril 2024November 2024Allow720YesNo
18642074NOVEL THERAPYApril 2024July 2025Abandon1401NoNo
18642051In Vitro and Xenograft Anti-Tumor Activity of a Halogenated-Xanthene Against Refractory Pediatric Solid TumorsApril 2024May 2025Allow1310YesNo
18636148METHODS AND COMPOSITIONS FOR REDUCING SYMPTOMS OF PARKINSON'S DISEASEApril 2024August 2024Allow410NoNo
18635779CONTROLLED RELEASE FORMULATION AND MINIMALLY INVASIVE METHOD OF ADMINISTRATIONApril 2024July 2024Allow310NoNo
18629507HUMAN THERAPEUTIC AGENTSApril 2024June 2025Abandon1410NoNo
18626876LIQUID ORAL FORMULATIONS FOR SILDENAFILApril 2024November 2024Allow710YesNo
18624045(2E)-4-[(4-CHLOROPHENYL)AMINO]-N-PHENYL-2-(PHENYLIMINO)-1,3,5-DIOXAZEPINE-7-CARBOXAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)April 2024June 2024Allow200NoNo
18696857VANIN-1 INHIBITORMarch 2024June 2024Allow200YesNo
18620393COMPOSITIONS CONTAINING PARAXANTHINE AND BETA-HYDROXYBUTYRATE OR PRECURSOR FOR INCREASING NEUROLOGICAL AND PHYSIOLOGICAL PERFORMANCEMarch 2024July 2024Allow300YesNo
18614911MACROCYCLIC COMPOUNDS AND METHODS OF USEMarch 2024July 2024Allow400NoNo
18604704ISATIN DERIVATIVESMarch 2024April 2025Allow1410NoNo
18600301TREATING SAR-COV-2 RELATED HEALTH PROBLEMSMarch 2024May 2025Abandon1410NoNo
18595919USE OF THYROID BETA-AGONISTSMarch 2024July 2025Allow1611NoNo
18590435BUPROPION AND DEXTROMETHORPHAN FOR TREATING NICOTINE ADDICTIONFebruary 2024May 2025Abandon1420YesNo
18590806COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES FOR TUBULIN-TARGETED THERAPY IN THE TREATMENT OF CANCERS AND RELATED CONDITIONSFebruary 2024September 2024Allow711YesNo
18589348BUPROPION AND DEXTROMETHORPHAN FOR TREATING NICOTINE ADDICTIONFebruary 2024June 2025Abandon1620NoNo
18587006METHODS OF TREATING OBESITY USING ANTIOXIDANT INFLAMMATION MODULATORSFebruary 2024July 2025Abandon1601NoNo
18583976S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS FOR TREATING AMYOTROPHIC LATERAL SCLEROSISFebruary 2024March 2025Allow1310NoNo
18582125METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESSFebruary 2024November 2024Abandon910NoNo
18444104ORAL FORMULATIONS OF FASUDIL WITH ION EXCHANGE RESINFebruary 2024June 2024Allow410NoNo
18443889HYDROCORTISONE ORAL LIQUID FORMULATIONSFebruary 2024September 2024Allow710NoNo
18441600TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITEFebruary 2024June 2024Allow400YesNo
18441611TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITEFebruary 2024July 2024Allow500YesNo
18441621TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITEFebruary 2024July 2024Allow500YesNo
18441597TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITEFebruary 2024August 2024Allow600YesNo
184305271-(2-HYDROXYBENZYLIDENEAMINO)-5-PHENYLIMIDAZOLIDINE-2,4-DIONE AS AN ANTIMICROBIAL COMPOUNDFebruary 2024April 2024Allow200NoNo
184259846'(4-METHOXYPHENYL)-2'-ALKOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS ANTIMICROBIAL COMPOUNDSJanuary 2024June 2024Allow6000NoNo
184259236'(4-METHOXYPHENYL)-2'-ALKOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS ANTIMICROBIAL COMPOUNDSJanuary 2024May 2024Allow400NoNo
184232014-[4,4-BIS(4-CHLOROPHENYL)-2,5-DIOXOIMIDAZOLIDIN-1-YL]BUTANOIC ACID AS AN ANTIMICROBIAL COMPOUNDJanuary 2024August 2024Allow701YesNo
18420370TIMOLOL MALEATE GEL FOR TOPICAL ADMINISTRATIONJanuary 2024January 2025Allow1120YesNo
18418901FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITISJanuary 2024June 2025Allow1610YesNo
18414316Prevention And Treatment Of Atrial Fibrillation/Flutter With Gamma-Ketoaldehyde ScavengersJanuary 2024May 2025Abandon1610NoNo
18411576PSILOCIN MUCATEJanuary 2024August 2024Allow711NoNo
184115012,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOFJanuary 2024April 2025Allow1510YesNo
18408929TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASEJanuary 2024April 2025Allow1511NoNo
18577088A System and Method for Measuring and Stimulating AutophagyJanuary 2024June 2025Abandon1711NoNo
18405787EFFECTIVE ANTICANCER DRUG CANDIDATE OF DINUCLEAR PALLADIUM (II) BIS-DIHYDROZONE MALONYL COMPLEXJanuary 2024April 2024Allow300YesNo
184042831-(4-CARBONOIMIDOYLPHENOXY)-3-{4-[(E)-(PHENYLIMINO)METHYL]PHENOXY}PROPAN-2-OL AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)January 2024April 2024Allow301YesNo
18402989ETHYL 3-[4,4-BIS(4-CHLOROPHENYL)-2,5-DIOXOIMIDAZOLIDIN-1-YL]PROPANOATE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024March 2024Allow300NoNo
18403049O-{1-[(3,5-DINITROBENZOYL)AMINO]PROPAN-2-YL} (4-CHLOROPHENYL)CARBAMOTHIOATE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)January 2024April 2024Allow310NoNo
18399505IMIDAZO[1,2-A]PYRAZINE COMPOUNDS AS CK2 INHIBITORSDecember 2023July 2024Allow620NoNo
18397710(2E)-4-[(4-CHLOROPHENYL)AMINO]-N-PHENYL-2-(PHENYLIMINO)-1,3,5-DIOXAZEPINE-7-CARBOXAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)December 2023March 2024Allow201YesNo
18393556METHODS FOR INHIBITING FASCINDecember 2023April 2025Allow1601NoNo
18390164METHODS OF TREATING HYPOGONADISM WITH TRANSNASAL TESTOSTERONE BIO-ADHESIVE GEL FORMULATIONS IN MALE WITH ALLERGIC RHINITIS, AND METHODS FOR PREVENTING AN ALLERGIC RHINITIS EVENTDecember 2023March 2025Abandon1510NoNo
18391243DRUG DELIVERY FORMULATIONSDecember 2023September 2024Allow920NoNo
18544874METHOD TO IDENTIFY AND ALLEVIATE THE SYMPTOMS OF PARKINSONISM/PARKINSON�S DISEASEDecember 2023December 2024Abandon1110NoNo
18534234METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESSDecember 2023January 2025Abandon1420NoNo
18533052WOUND DRESSING BASED ON POLYMERIC MIXTURE OF CELLULOSE ACETATE AND HYALURONIC ACID EMBEDDED WITH COPPER OXIDE AND MAGNESIUM OXIDE NANOPARTICLESDecember 2023December 2024Allow1220NoNo
18530071PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFDecember 2023October 2024Abandon1110NoNo
18526686NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSDecember 2023July 2024Allow710YesNo
18521768METHODS AND COMPOSITIONS FOR REDUCING TOLERANCE TO OPIOID ANALGESICS USING IBOGAINE AND DERIVATIVES THEREOFNovember 2023May 2025Abandon1710NoNo
18521462SYNTHETIC ROUTE TO 4,4'-DIIODOAZOBENZENE VIA HOMO-OXIDATIVE CROSS-COUPLING OF ARYL DIAZONIUM SALT USING CU-CATALYZED SANDMEYER-STYLE REACTIONNovember 2023April 2024Allow410NoNo
18520091METHOD OF TREATING A PERSON AFFLICTED WITH A RESPIRATORY CONDITION AND PHARMACEUTICAL FORMULATION INCLUDING DAPSONENovember 2023April 2025Allow1710YesNo
18518044MEDIUM CHAIN TRIGLYCERIDE COMPOSITIONSNovember 2023November 2024Allow1200YesNo
185110899-(2-HYDROXYQUINOLIN-3-YL)-10-(2-HYDROXYETHYL)-3,3,6,6-TETRAMETHYL-3,4,6,7,9,10-HEXAHYDROACRIDINE1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDNovember 2023March 2024Allow411YesNo
18508830BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONSNovember 2023April 2025Allow1710YesNo
18389167EMULSION FORMULATIONSNovember 2023March 2025Allow1610YesNo
18506164Bicyclic Compounds and their UsesNovember 2023June 2025Allow1901NoNo
18503626PYRIMIDINE BASED MODULATORS AND USES THEREOFNovember 2023June 2024Allow701NoNo
18387170COMBINATION THERAPIESNovember 2023December 2024Abandon1311NoNo
18501814IMMEDIATE AND CONTROLLED RELEASE APPETITE SUPPRESSANT COMPOSITIONS FOR WEIGHT LOSSNovember 2023February 2025Allow1511YesNo
18386017(E)-1-(2-(4-SUBSTITUTEDPHENYL)-2-OXOETHYL)-4-((HYDROXYIMINO)METHYL)PYRIDINIUM BROMIDES AS ANTITUBERCULAR AGENTSNovember 2023October 2024Abandon1211NoNo
183856488-(3-BROMOBENZYLIDENEAMINO)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUNDOctober 2023January 2024Allow300NoNo
18497602Pyrrolo[1,2-c]imidazole derivatives as orexin type 2 receptor agonistsOctober 2023March 2024Allow501NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1627.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
414
Examiner Affirmed
294
(71.0%)
Examiner Reversed
120
(29.0%)
Reversal Percentile
32.4%
Lower than average

What This Means

With a 29.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1879
Allowed After Appeal Filing
365
(19.4%)
Not Allowed After Appeal Filing
1514
(80.6%)
Filing Benefit Percentile
4.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 19.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1627 - Prosecution Statistics Summary

Executive Summary

Art Unit 1627 is part of Group 1620 in Technology Center 1600. This art unit has examined 15,223 patent applications in our dataset, with an overall allowance rate of 47.9%. Applications typically reach final disposition in approximately 32 months.

Comparative Analysis

Art Unit 1627's allowance rate of 47.9% places it in the 5% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1627 receive an average of 1.99 office actions before reaching final disposition (in the 65% percentile). The median prosecution time is 32 months (in the 31% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.